For at least the last six months, the two leading contenders in the battle for GLP-1 agonist supremacy in diabetes and obesity – Novo Nordisk A/S and Eli Lilly and Company – reported their quarterly results in the same week or even on the same day. (Also see "Stock Watch: Where Novo And Lilly Lead, Others Follow" - Scrip, 21 November, 2023.) With Lilly reporting after Novo and many US funds confined to holding only US-domiciled stocks, the cumulatively good clinical and financial news from both companies seemed to benefit Lilly the most. But in fourth-quarter and full-year 2023 earnings season, Novo reported almost a week before Lilly in what appeared to be a successful move to establish clear blue reporting water between the two.
[Sidebar#SC149720]








